A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Clinical trial NCT03082300 · TERMINATED

Trial details

NCT number: NCT03082300
Sponsor: Astellas Pharma Global Development, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor (EGFR) Mutations

Start date: 2017-03-24
Primary completion: 2017-05-12
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.